Literature DB >> 16236599

Oxidative stress in blood platelets from schizophrenic patients.

A Dietrich-Muszalska1, B Olas, J Rabe-Jablonska.   

Abstract

Oxidative stress in blood platelets is observed in various diseases, including neuropsychiatric disorders. The aim of our study was to evaluate oxidative stress in blood platelets from patients with schizophrenic disorders by measuring the activity of the platelet antioxidative enzyme, superoxide dismutase (SOD), concomitant with the level of thiobarbituric acid reactive species (TBARS). In blood platelets obtained from schizophrenic patients (with paranoid schizophrenia according to DSM-IV criteria) and from healthy volunteers the level of reactive oxygen species was also measured via chemiluminescence. In resting blood platelets from schizophrenic patients the chemiluminescence was higher than in platelets from control subjects (P < 0.05), but in thrombin-activated platelets an increase (about 53%) of chemiluminescence was observed, however this increase was lower than in thrombin-stimulated platelets from healthy subjects (101.5%). The results indicate that in platelets from schizophrenic patients generation of reactive oxygen species is enhanced. Moreover, we observed that SOD activity in blood platelets from schizophrenic patients was significantly lower than in control platelets and that a correlation exists between increased lipid peroxidation and inhibition of the activity of this antioxidative enzyme in schizophrenic platelets.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16236599     DOI: 10.1080/09537100500128872

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  22 in total

1.  MK-801 alters Na+, K+-ATPase activity and oxidative status in zebrafish brain: reversal by antipsychotic drugs.

Authors:  Kelly Juliana Seibt; Renata da Luz Oliveira; Denis Broock Rosemberg; Luiz Eduardo Baggio Savio; Emilene B S Scherer; Felipe Schmitz; Angela T S Wyse; Carla Denise Bonan
Journal:  J Neural Transm (Vienna)       Date:  2011-12-06       Impact factor: 3.575

2.  Epicatechin inhibits human plasma lipid peroxidation caused by haloperidol in vitro.

Authors:  Anna Dietrich-Muszalska; Bogdan Kontek; Beata Olas; Jolanta Rabe-Jabłońska
Journal:  Neurochem Res       Date:  2011-11-12       Impact factor: 3.996

Review 3.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

Review 4.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

Review 5.  Accelerated aging in schizophrenia patients: the potential role of oxidative stress.

Authors:  Olaoluwa O Okusaga
Journal:  Aging Dis       Date:  2013-12-04       Impact factor: 6.745

6.  The effects of ziprasidone, clozapine and haloperidol on lipid peroxidation in human plasma (in vitro): comparison.

Authors:  Anna Dietrich-Muszalska; Justyna Kopka; Anna Kwiatkowska
Journal:  Neurochem Res       Date:  2013-04-26       Impact factor: 3.996

7.  Meta-analysis of oxidative stress in schizophrenia.

Authors:  Joshua Flatow; Peter Buckley; Brian J Miller
Journal:  Biol Psychiatry       Date:  2013-05-15       Impact factor: 13.382

Review 8.  Antioxidants as potential therapeutics for neuropsychiatric disorders.

Authors:  Chirayu D Pandya; Kristy R Howell; Anilkumar Pillai
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-11-02       Impact factor: 5.067

9.  Schizophrenia genomics and proteomics: are we any closer to biomarker discovery?

Authors:  Shaheen E Lakhan; Alon Kramer
Journal:  Behav Brain Funct       Date:  2009-01-07       Impact factor: 3.759

Review 10.  Role of melatonin in schizophrenia.

Authors:  Armando L Morera-Fumero; Pedro Abreu-Gonzalez
Journal:  Int J Mol Sci       Date:  2013-04-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.